Compugen LtdNASDAQ:CGEN
- LAST PRICE1.4500
- TODAY'S CHANGE (%)0.0200 (1.3986%)
- Bid / Lots1.3900/ 2
- Ask / Lots1.5900/ 1
- Open / Previous Close1.4300 / 1.4300
- Day Range
- 52 Week Range
- Volume145,843
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CGEN |
|---|---|---|
| 09:32 ET | 2177 | 1.43 |
| 09:37 ET | 4925 | 1.41 |
| 09:39 ET | 896 | 1.4139 |
| 09:42 ET | 20037 | 1.44 |
| 09:44 ET | 355 | 1.4295 |
| 09:51 ET | 600 | 1.4195 |
| 09:57 ET | 100 | 1.42 |
| 10:00 ET | 300 | 1.42 |
| 10:02 ET | 10940 | 1.44 |
| 10:04 ET | 2383 | 1.42 |
| 10:06 ET | 125 | 1.4168 |
| 10:08 ET | 600 | 1.42 |
| 10:09 ET | 200 | 1.414671 |
| 10:13 ET | 240 | 1.42 |
| 10:15 ET | 700 | 1.42 |
| 10:31 ET | 14799 | 1.42 |
| 10:33 ET | 7575 | 1.44 |
| 10:38 ET | 200 | 1.44 |
| 10:42 ET | 350 | 1.4307 |
| 10:47 ET | 714 | 1.44 |
| 11:30 ET | 3452 | 1.46 |
| 11:32 ET | 1685 | 1.46 |
| 11:34 ET | 100 | 1.47 |
| 11:36 ET | 200 | 1.46 |
| 11:43 ET | 100 | 1.47 |
| 11:50 ET | 100 | 1.46 |
| 11:54 ET | 100 | 1.46 |
| 11:56 ET | 180 | 1.4567 |
| 11:59 ET | 300 | 1.465 |
| 12:03 ET | 100 | 1.47 |
| 12:12 ET | 1333 | 1.47 |
| 12:14 ET | 1016 | 1.49 |
| 12:24 ET | 200 | 1.49 |
| 12:35 ET | 750 | 1.5 |
| 12:37 ET | 857 | 1.5107 |
| 12:39 ET | 100 | 1.515 |
| 12:44 ET | 5436 | 1.51 |
| 12:46 ET | 557 | 1.505 |
| 12:51 ET | 14887 | 1.48 |
| 12:57 ET | 275 | 1.48 |
| 01:00 ET | 647 | 1.5 |
| 01:18 ET | 100 | 1.5 |
| 01:24 ET | 1067 | 1.5 |
| 01:29 ET | 200 | 1.5 |
| 01:33 ET | 3286 | 1.5 |
| 01:36 ET | 565 | 1.5 |
| 01:40 ET | 330 | 1.499 |
| 01:42 ET | 367 | 1.5 |
| 01:44 ET | 590 | 1.4923 |
| 01:51 ET | 103 | 1.495 |
| 01:54 ET | 2900 | 1.4806 |
| 02:02 ET | 500 | 1.48 |
| 02:09 ET | 800 | 1.48 |
| 02:14 ET | 444 | 1.4706 |
| 02:20 ET | 300 | 1.47 |
| 02:25 ET | 200 | 1.465 |
| 02:39 ET | 1500 | 1.465 |
| 02:41 ET | 800 | 1.46 |
| 02:43 ET | 1296 | 1.4629 |
| 02:50 ET | 400 | 1.46 |
| 03:12 ET | 100 | 1.46 |
| 03:19 ET | 425 | 1.455 |
| 03:21 ET | 117 | 1.455 |
| 03:26 ET | 350 | 1.455 |
| 03:30 ET | 1234 | 1.45 |
| 03:33 ET | 500 | 1.45 |
| 03:35 ET | 100 | 1.445 |
| 03:39 ET | 300 | 1.445 |
| 03:46 ET | 309 | 1.445 |
| 03:48 ET | 741 | 1.445 |
| 03:50 ET | 100 | 1.45 |
| 03:53 ET | 100 | 1.45 |
| 03:55 ET | 3637 | 1.45 |
| 03:57 ET | 4467 | 1.455 |
| 04:00 ET | 2647 | 1.45 |
Nov 12, 2024
Compugen Reports Third Quarter 2024 Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: Compugen Reports Third Quarter 2024 Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
Compugen to Participate in Stifel 2024 Healthcare Conference, from 7:00AM ET on Monday Nov 11, 2024 by Dow Jones
7:00AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 5, 2024
Oct 29, 2024
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024, from 7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Compugen Ltd | 129.8M | 75.6x | --- |
Caribou Biosciences Inc | 179.3M | -1.2x | --- |
Nanobiotix SA | 176.8M | -3.3x | --- |
Fennec Pharmaceuticals Inc | 129.5M | -46.8x | --- |
Elutia Inc | 152.1M | -2.1x | --- |
TriSalus Life Sciences Inc | 129.8M | -2.6x | --- |
Company Information
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Contact Information
- Headquarters
- Azrieli Center, 26 Harokmim St., Bldg DHOLON, Israel 5885849
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Paul Sekhri
- President, Chief Executive Officer, Director
- Anat Cohen-Dayag
- Chief Financial Officer
- David Silberman
- Senior Vice President, Corporate and Business Development
- Oliver Froescheis
- Senior Vice President, Technology Innovation
- Zurit Levine
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $129.8M |
|---|---|
Revenue (TTM) | $59.9M |
Shares Outstanding | 89.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.59 |
EPS | $0.02 |
Book Value | $0.73 |
P/E Ratio | 75.6x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 17.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
